T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$3.3B |
| 2 |
Eli Lilly
LLY
|
+$2.75B |
| 3 |
AstraZeneca
AZN
|
+$1.98B |
| 4 |
Coupang
CPNG
|
+$1.54B |
| 5 |
Fortinet
FTNT
|
+$1.48B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NXP Semiconductors
NXPI
|
+$2.34B |
| 2 |
Morgan Stanley
MS
|
+$2.26B |
| 3 |
Airbnb
ABNB
|
+$2.04B |
| 4 |
Qualcomm
QCOM
|
+$1.95B |
| 5 |
NVIDIA
NVDA
|
+$1.81B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.55% |
| 2 | Healthcare | 16.29% |
| 3 | Consumer Discretionary | 15.56% |
| 4 | Financials | 12.85% |
| 5 | Communication Services | 12.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVYA
2076
DELISTED
Avaya Holdings Corp. Common Stock
AVYA
| $936K | ﹤0.01% |
33,402
+13,264
| +66% | +$355K |
|
2077
Impinj
PI
$5.49B
| $935K | ﹤0.01% |
16,440
+7,324
| +80% | +$431K |
|
|
PRO
2078
DELISTED
PROS Holdings
PRO
| $935K | ﹤0.01% |
21,994
-557
| -2% | -$25.4K |
|
2079
Wabash National
WNC
$507M
| $934K | ﹤0.01% |
49,697
+13,385
| +37% | +$237K |
|
2080
First Busey Corp
BUSE
$2.58B
| $933K | ﹤0.01% |
36,392
+7,770
| +27% | +$183K |
|
2081
AngioDynamics
ANGO
$647M
| $931K | ﹤0.01% |
39,798
-4,520
| -10% | -$91.4K |
|
|
COOP
2082
DELISTED
Mr. Cooper
COOP
| $931K | ﹤0.01% |
26,788
+9,201
| +52% | +$291K |
|
2083
Heron Therapeutics
HRTX
$63.5M
| $931K | ﹤0.01% |
57,421
-13,077
| -19% | -$233K |
|
2084
ArcBest
ARCB
$3.28B
| $930K | ﹤0.01% |
13,214
+1,301
| +11% | +$75K |
|
2085
Central Garden & Pet Co Class A
CENTA
$2.43B
| $929K | ﹤0.01% |
22,370
+92
| +0.4% | +$3.15K |
|
2086
OFG Bancorp
OFG
$2.26B
| $923K | ﹤0.01% |
40,807
-84
| -0.2% | -$1.67K |
|
|
VIVO
2087
DELISTED
Meridian Bioscience Inc
VIVO
| $922K | ﹤0.01% |
35,115
+2,693
| +8% | +$64K |
|
2088
AdaptHealth
AHCO
$760M
| $921K | ﹤0.01% |
25,065
+13,960
| +126% | +$493K |
|
2089
TTEC Holdings
TTEC
$77.4M
| $916K | ﹤0.01% |
9,117
-8,880
| -49% | -$754K |
|
|
PINC
2090
DELISTED
Premier
PINC
| $915K | ﹤0.01% |
27,043
+955
| +4% | +$33.1K |
|
|
SRNE
2091
DELISTED
Sorrento Therapeutics, Inc.
SRNE
| $914K | ﹤0.01% |
110,484
-7,891
| -7% | -$83.3K |
|
|
AMRN
2092
Amarin Corp
AMRN
$297M
| $908K | ﹤0.01% |
7,312
-66,573
| -90% | -$8.95M |
|
2093
BGC Group
BGC
$5.12B
| $906K | ﹤0.01% |
187,479
+8,919
| +5% | +$38K |
|
2094
Myriad Genetics
MYGN
$309M
| $906K | ﹤0.01% |
29,757
-11,221
| -27% | -$318K |
|
2095
Horace Mann Educators
HMN
$2.09B
| $903K | ﹤0.01% |
20,909
-2,398
| -10% | -$99.2K |
|
|
STAY
2096
DELISTED
Extended Stay America, Inc. Paired Share Unit
STAY
| $902K | ﹤0.01% |
45,673
+3,811
| +9% | +$62.2K |
|
2097
CVR Energy
CVI
$3.52B
| $901K | ﹤0.01% |
46,952
+3,725
| +9% | +$75.7K |
|
|
GWB
2098
DELISTED
Great Western Bancorp, Inc.
GWB
| $901K | ﹤0.01% |
29,753
-1,110
| -4% | -$30.2K |
|
2099
Nu Skin
NUS
$236M
| $899K | ﹤0.01% |
16,994
+316
| +2% | +$17.2K |
|
|
POLY
2100
DELISTED
Plantronics, Inc.
POLY
| $899K | ﹤0.01% |
23,101
-4,807
| -17% | -$181K |
|
Similar funds
T. Rowe Price Associates's Q1 2021 Portfolio in Review
As of Q1 2021, T. Rowe Price Associates held 2,908 positions worth $999B, up 2.5% from $974B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
T. Rowe Price Associates's Q1 2021 filing shows 248 new, 1,171 increased, 1,334 reduced and 66 closed positions. Its largest new stake was Coupang: 33,380,859 shares worth $1.63B. The largest sale was NXP Semiconductors, an estimated $2.34B.
By sector, the portfolio is most concentrated in Technology at 24% of assets, down from 25% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2021 buy was Coupang: 33,380,859 shares worth $1.63B.
- T. Rowe Price Associates added most to Zoom in Q1 2021, an estimated $3.3B increase.
- T. Rowe Price Associates's biggest Q1 2021 reduction was NXP Semiconductors, cutting an estimated $2.34B.
- T. Rowe Price Associates fully exited CONCHO RESOURCES INC. in Q1 2021, selling an estimated $205M.
- T. Rowe Price Associates's ten largest holdings make up 24% of its $999B portfolio in Q1 2021.
- T. Rowe Price Associates opened 248 new positions and closed 66 in Q1 2021.
- T. Rowe Price Associates's portfolio value rose 2.5% quarter-over-quarter to $999B.
Based on T. Rowe Price Associates's 13F filing for Q1 2021, filed 17 May 2021.